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Osteoradionecrosis of the Mandible 
Minimized Risk Profile Following Intensity-Modulated Radiation Therapy (IMRT)
Gabriela Studer1, Stephan Philipp Studer2, Roger Arthur Zwahlen2, Pia Huguenin1, Klaus Wilhelm Grätz2, 
Urs Martin Lütolf1, Christoph Glanzmann1 
Background and Purpose: Osteoradionecrosis (ON) of the mandible is a serious late complication of high-dose radiation thera-
py for tumors of the oropharynx and oral cavity. After doses between 60 and 72 Gy using standard fractionation, an incidence of 
ON between 5% and 15% is reported in a review from 1989, whereas in more recent publications using moderately accelerated or 
hyperfractionated irradiation and doses between 69 and 81 Gy, the incidence of ON is between < 1% and ~ 6%. Intensity-modu-
lated radiation therapy (IMRT) is expected to translate into a further important reduction of ON. The aim of this descriptive study 
was to assess absolute and relative bone volumes exposed to high IMRT doses, related to observed bone tolerance.
Patients and Methods: Between December 2001 and November 2004, 73 of 123 patients treated with IMRT were identified as 
subgroup “at risk” for ON (> 60 Gy for oropharyngeal or oral cavity cancer). 21/73 patients were treated in a postoperative setting, 
52 patients underwent primary definitive irradiation. In 56 patients concomitant cisplatin-based chemotherapy was applied. 
Mean follow-up time was 22 months (12–46 months). Oral cavity including the mandible bone outside the planning target volume 
was contoured and dose-volume constraints were defined in order to spare bone tissue. Dose-volume histograms were obtained 
from contoured mandible in each patient and were analyzed and related to clinical mandible bone tolerance. 
Results: Using IMRT with doses between 60 and 75 Gy (mean 67 Gy), on average 7.8, 4.8, 0.9, and 0.3 cm3 were exposed to doses 
> 60, 65, 70, and 75 Gy, respectively. These values are substantially lower than when using three-dimensional conformal radiother-
apy. The difference has been approximately quantified by comparison with a historic series. Additional ON risk factors of the pa-
tients were also analyzed. Only one grade 3 ON of the lingual horizontal branch, treated with lingual decortication, was observed. 
Conclusion: Using IMRT, only very small partial volumes of the mandibular bone are exposed to high radiation doses. This is 
expected to translate into a further reduction of ON and improved osseointegration of dental implants. 
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Osteoradionekrose der Mandibula. Geringeres Risiko durch intensitätsmodulierte Radiotherapie (IMRT) 
Hintergrund und Ziel: Die Osteoradionekrose (ON) des Unterkiefers ist eine schwerwiegende Komplikation kurativer normofrak-
tionierter Radiotherapie von Oropharynx- und Mundhöhlenkarzinomen. Nach Dosen zwischen 60 und 72 Gy besteht gemäß den 
Angaben einer Übersicht aus dem Jahr 1989 eine ON-Inzidenz von 5–15%, während laut neueren Arbeiten über leicht akzelerier-
te oder hyperfraktionierte Behandlungsschemata mit Dosen von 69–81 Gy die ON-Inzidenz zwischen < 1% und ca. 6% beträgt. 
Intensitätsmodulierte Radiotherapie (IMRT) dürfte die ON-Rate weiter reduzieren. Ziel dieser deskriptiven Arbeit war, absolute 
und relative Knochenvolumina mit hoher Dosisexposition zu evaluieren und in Beziehung zur beobachteten Knochentoleranz der 
eigenen Patienten nach IMRT-Behandlung zu setzen. 
Patienten und Methodik: Zwischen Dezember 2001 und November 2004 wurden an der eigenen Klinik 123 Patienten mit Tumo-
ren der Kopf-Hals-Region mit IMRT behandelt; hiervon waren 73 einer Untergruppe von Patienten mit Risiko für ON zuzurechnen 
(Karzinome des Oropharynx oder der Mundhöhle und Herddosen > 60 Gy). 21 Patienten wurden postoperativ, 52 primär kurativ 
bestrahlt; 56 erhielten eine simultane cisplatinbasierte Chemotherapie. Die mittlere Beobachtungszeit betrug 22 Monate (12–46 
Monate). Die Mundhöhle inkl. Kieferknochen außerhalb des Planungszielvolumens wurde konturiert, und Dosis-Volumen-Bedin-
gungen zur Organschonung wurden festgelegt. Retrospektiv wurde für jeden Patienten das gesamte Kieferknochenvolumen kon-
turiert, und die Dosis-Volumen-Histogramme wurden im Hinblick auf die klinische Knochentoleranz ausgewertet. 
Ergebnisse: Durch IMRT in Dosen zwischen 60 und 75 Gy (Mittelwert 67 Gy) wurden im Mittel 7,8, 4,8, 0,9 und 0,3 cm3 einer 
Dosis von > 60, 65, 70 und 75 Gy ausgesetzt (Tabelle 1 und Abbildung 1). Diese Werte sind deutlich kleiner als nach konventio-
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Introduction 
Delivering high doses (> 60 Gy) with moderately accelerated 
or hyperfractionated schedules with three-dimensional con-
formal radiotherapy (3D-CRT) techniques, as in use since 
about 1990, the incidence of osteoradionecrosis (ON) could 
be reduced from approximately 15% to about 5% [1]. 
In several large prospective studies on fractionation regi-
mens or combined chemoradiation studies using 3D-CRT 
since about 1990 in patients with carcinoma of the oropharynx 
or oral cavity, an incidence of ON between < 1% and approxi-
mately 6% has been observed [19, 20]. In our patients receiv-
ing hyperfractionated radiotherapy to a total dose between 72 
and 76.8 Gy, incidence of ON was 20.1% (51% if there were 
teeth in the irradiated bone). An increased ON risk has been 
described when more than half of the horizontal branch of the 
mandible is exposed to high doses [7]. In a more recent analy-
sis that included hyperfractionated and accelerated 3D-CRT 
schedules until 2002 [19], a correlation with exposed bone vol-
ume was not clearly evident, probably due to the small sample 
size of events. According to Emami et al. [5] the dose for a risk 
of 5% in 5 years (TD5/5) is 65 or 60 Gy if one third or at least 
two thirds of the mandible are exposed, whereas the TD50/5 is 
77 or 72 Gy if one third or at least two thirds of the mandible 
are exposed. 
Cisplatin- and 5-fluorouracil-based chemotherapy is not 
reported to influence the ON risk. 
Using intensity-modulated radiotherapy (IMRT), dose-
volume relationships are expected to substantially improve in 
favor of the mandible bone, while a similar or better target 
coverage is achieved compared to 3D-CRT. Using dose-vol-
ume constraints for mandible bone-sparing purposes, doses to 
the mandible, as well as mandible bone volumes exposed to 
relevant doses are hypothesized to be reducible to a non-
critical value in all patients except those with bone-infiltrating 
tumors or large tumors close to the bone. 
Early experiences in IMRT with respect to mandible bone 
tolerance are presented. 
Patients and Methods 
Patients 
Out of 123 head-and-neck cancer patients undergoing IMRT 
between December 2001 and November 2004, a subgroup of 
73 patients “at risk” for ON has been analyzed. Mean fol-
low-up time was 22 months (range 12–46 months). Based on 
our past experience [19], we considered the following patients 
“at risk” of developing ON following radiation therapy: pa-
tients with primary tumor of the oral cavity (n = 18) or oro-
pharynx (n = 55) who completed their IMRT course to a pre-
scribed total dose (PTD) of at least 60 Gy (n = 2; 64 patients 
≥ 66 Gy). In our previous series, no ON events were observed 
in irradiated nasopharyngeal and hypopharyngeal cancer pa-
tients [7, 19]. Additional potential risk cofactors were assessed 
(tumor invasion into the mandible bone, tumor close to bone, 
entire bone diameter exposed to ≥ 95% of PTD, bone volume 
exposed to doses > 70 Gy, teeth in high-dose bone areas). 
IMRT was delivered using simultaneously integrated 
boost technique (SIB-IMRT). 52 of the 73 patients underwent 
primary definitive irradiation, the remaining 21 were treated 
in a postoperative setting. 37/73 patients (50%) presented with 
a locally advanced stage T3/4. In five cases with a T1/2 prima-
ry, extensive nodal disease (N2c) was diagnosed. Six patients 
were treated for recurrent disease. The remaining 25 patients 
suffered from an early-stage tumor (T1–2 N0–2b). Gender ra-
tio was 1 : 4 in favor of men (14 women vs. 59 men), mean age 
was 60.2 years (41–85 years). In 56 patients (77%) concomi-
tant cisplatin-based chemotherapy was applied. In the major-
ity of patients, a positron emission tomography (PET) was 
available for radiation treatment planning [10]. All patients 
were regularly followed in collaboration with surgeons of our 
head-and-neck surgery or maxillofacial surgery joint clinics. 
Follow-up intervals were 2 and 6 weeks after IMRT comple-
tion, then every 2–3 months. Toxicity assessments were per-
formed using the EORTC/RTOG toxicity criteria. 
Radiation Planning and Treatment 
Planning Computed Tomography (CT) 
Planning CT (Somatom Plus 4, Siemens, Erlangen, Germany) 
was performed with 2 mm slice thickness and no interslice gap 
throughout the whole sequentially acquired region of interest, 
with the patient immobilized in a commercially available ther-
moplastic mask including head and shoulder region, and with 
an integrated individually customized bite block. 
Planning systems: Contouring and plan optimization were 
performed on a Varian Treatment Planning System (Eclipse®, 
Version 7.3.10, Varian Medical System, Hansen Way, Palo Al-
to, CA, USA. 
neller Bestrahlung. Der Unterschied wurde im Vergleich mit einer historischen Serie näherungsweise quantifiziert (Abbildung 3). 
Zusätzliche Risikofaktoren der eigenen Patienten wurden analysiert (Abbildung 2). Nur ein ON-Ereignis (Grad 3) im Bereich des 
lingualen Horizontalasts der Mandibula wurde beobachtet und erfolgreich mit einer lingualen Dekortikation behandelt. 
Schlussfolgerung: Mittels IMRT werden nur sehr kleine Knochenvolumina hohen Bestrahlungsdosen ausgesetzt. Durch diese 
Knochenschonung werden eine weitere Reduktion des ON-Risikos und eine höhere Erfolgsrate rekonstruktiver Zahnimplantate 
(Tabelle 2) erwartet. 
Schlüsselwörter:  Osteoradionekrose · IMRT · Normalgewebstoleranz · Kieferknochen · Zahnimplantate 
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Delineation of Planning Target Volumes (PTVs) 
Definitions: 
• GTV = gross tumor volume; 
•  CTV = clinical target volume for elective lymph nodes (vol-
ume definitions according to the recommendations of Gre-
goire et al. [9]); 
• PTV = planning target volume; 
• PTV1 = GTV plus 10–15 mm; 
• PTV2 = CTV plus 5–10 mm for doses between 48–56 Gy. 
Dose Constraints for Normal Tissues/Organs at Risk (OARs) 
Irradiation planning aimed at target doses of 60–70 Gy re-
specting the tolerance limits as follows: 
•  spinal cord: Dmax < 45 Gy , Dmean < 35 Gy (spinal cord was 
contoured at least with a 5- to 10-mm margin, usually > 10 mm 
at the ventral aspect); 
•  parotid (entire or partial) gland volume, spared to the de-
gree possible without compromising target coverage: Dmean 
≤ 26 Gy; 
• temporomandibular joint (TMJ): Dmax < 50 Gy; 
• brain: Dmax < 40 Gy; 
•  oral cavity outside the PTV: Dmean < 35 Gy, contouring of the 
oral cavity also included the mandibular and maxillary bone 
and the oral vestibule; 
• nuchal tissue: Dmean < 45 Gy. 
In order to obtain complete dose-volume histograms 
(DVHs) for the recent analysis, the entire mandible volume 
was retrospectively contoured in each patient. 
Radiation 
Irradiation was delivered by 6-MeV photon beams on a Varian 
linear accelerator with sliding window MLC (multileaf collima-
tor) technique. Technical solution resulted in five-field arrange-
ments (“class solution”) for most patients (n = 61), six fields were 
applied in five, seven fields in seven patients. 
In all patients, SIB-IMRT technique was performed using 
the following schedules: 
• 30 × 2.2/1.8 Gy to 66 Gy (PTV1)/54 Gy (PTV2; n = 28); 
• 33 × 2.11/1.64 Gy to 69.6 Gy/54 Gy (n = 25); 
• 30 × 2.11/1.8 Gy to 63.3/54 Gy (n = 3); 
• 30–35 × 2.0 Gy to 60–70 Gy (n = 16 postoperative patients).
In one case with large necrotic nodes, a higher SIB dose 
of 2.35 Gy per fraction to 75.2 Gy to the nodal GTV was 
chosen. 
PTV homogeneity was aimed to be in accordance with the 
RTOG guidelines: 
•  the prescription dose is the isodose which encompasses at 
least 95% of the PTV; 
•  no more than 20% of any PTV will receive > 110% of its 
prescribed dose; 
•  no more than 1% of any PTV will receive < 93% of its pre-
scribed dose; 
•  no more than 1% or 1 cm3 of the tissue outside the PTV will 
receive > 110% of the dose prescribed to the primary PTV. 
Dental Care Prior to Radiation Therapy 
All patients were seen in the Outpatient Clinic of the Depart-
ment of Oral and Maxillofacial Surgery. Dental treatment 
following Daly’s guidelines was performed [3]. Patients were 
provided with an individual fluoride carrier and were in-
structed in dental care. During the RT course these patients 
had one to two appointments for oral hygiene. 
Amifostine or saliva substitutes were not used [15, 16].
Methods 
DVHs of the whole mandibular bone were obtained by 
contouring the entire mandible in each patient’s planning 
CT. DVHs were analyzed with respect to volumes (cm3) 
and percentage of volume of the mandible. Data were relat-
ed to the observed mandibular bone tolerance. In 63/73 
cases complete dosimetric and volumetric data were avail-
able; of the remaining ten data sets, two were not evaluable 
due to mandibular resection prior to irradiation, and eight 
Table 1. Doses delivered to partial volumes (in cm3) of the mandibular 
bone. Note that in nine patients with a mean tumor dose of 64.8 Gy, 
< 60 Gy was delivered to the mandibular bone. 
Tabelle 1. Volumina (in cm3) der mit den angegebenen Dosen bestrahl-
ten Kieferknochen. Anzumerken ist, dass bei neun Patienten mit einer 
mittleren Tumordosis von 64,8 Gy der Kieferknochen mit < 60 Gy be-
lastet wurde. 
 < 60 Gy > 60 Gy > 65 Gy > 70 Gy > 75 Gy
Mandibles (n) 9 52 48 27 6
Mean volume (cm3)  7.8 4.8 0.9 0.29
Range (cm3)  0.3–23.7 0.1–16.8 0.1–6.0 0.1–0.75
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Figure 1. Dose-volume histogram-(DVH-)based bone volumes (in cm3) 
of 54/63 mandibles exposed to IMRT doses > 60, > 65, > 70, and > 75 Gy, 
respectively. In nine cases, doses to the mandible could be kept < 60 Gy 
(in seven of these nine patients, the tumor dose was > 66 Gy [range 
60–69.6 Gy]). 
Abbildung 1. Dosis-Volumen-Histogramm-(DVH-)basierte Kiefervolu-
mina von 54 der 63 analysierten Kieferknochen: Dargestellt sind Vo-
lumina, die Dosen > 60, > 65, > 70 und > 75 Gy ausgesetzt waren. Bei 
neun Patienten konnte die Kieferdosis < 60 Gy gehalten werden (bei 
Tumordosen > 66 Gy [60–69,6 Gy] in sieben der neun Fälle). 
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were lost due to a malfunctioning electronic transfer from 
the data bank. 
Results 
Dosimetry of the Mandible 
The mean mandibular volume was 58.4 cm3, ranging be-
tween 33 and 88 cm3, mean GTV measured 31.6 cm3 (range 
2–132 cm3), and the mean SIB volume (PTV1) was 164 cm3 
(range 31–393 cm3), respectively. 
In 42 patients a mean mandible volume of 4.6% (range 
0.5–15%) received > 100% of the PTD. Only 16 of those 42 
mandibles were exposed to doses > 105% (mean 1.7%, range 
0.1–4% of the bone volume). Mean Dmax in all patients was 
71.0 Gy (range 59.6–80 Gy), and mean Dmean 38.3 Gy (range 
17.9–56 Gy). 
Absolute doses delivered to partial volumes of the man-
dibular bone (in cm3) are shown in Table 1. In Figure 1, abso-
lute bone volumes exposed to doses > 60, 65, 70, and 75 Gy are 
analyzed. 
Figure 2 shows the risk profile of the cohort. Patients were 
grouped according to five risk factors in addition to a mandi-
ble dose > 60 Gy. 
In 9/63 cases (15%) doses to the mandible were < 60 Gy 
and therefore bone was not at risk. 
Mandibular Bone Tolerance 
Only a single patient with a radiation-associated bone event 
has been observed, following SIB-IMRT with 30 × 2.2 Gy to a 
total dose of 66 Gy for a T3 N2b base of tongue carcinoma. 
Grade 3 ON (bone necrosis of the exposed superficial cortical 
bone, needing decortication of the lingual corticalis) occurred 
6 months after IMRT completion, and was surgically com-
pletely resolved by a transoral local bone decortication. Mean 
and maximum mandibular doses were 42 Gy and 74 Gy, re-
spectively. A small bone volume of 0.36 cm3 received > 65 Gy, 
only 0.18 cm3 > 70 Gy (106% of prescribed dose), however, 
there was a hot spot of 115% delivered to the adjacent muco-
sal tissue of the ipsilateral floor of mouth as a theoretical 
source of tissue damage. No teeth were in 
the high-dose area, and no SIB dose was 
delivered to the corresponding buccal 
cortex, classifying this patient for risk 
group 1 (Figure 2). 
Locoregional Control 
Locoregional tumor control was achieved 
in 59/73 patients (~ 80%) after a mean 
overall observation time of 22 months 
(12–46 months). 3/12 patients with lo-
coregional failure also had distant metas-
tases. When local control was analyzed 
according to the tumor entity, 9/18 oral 
cavity tumors (50%), and 3/55 oropha-
ryngeal tumors (~ 5%) failed.
Discussion 
This is the first report on relative and 
absolute dose-volume relationships in 
IMRT-spared mandibular bone. 
Dosimetric data published on irradi-
ated mandible bone volumes are sparse.
Jereczek-Fossa et al. measured dose 
distributions of the mandible in 18 oro-
pharyngeal cancer patients treated with 
bifractionated 3D-CRT (62 × 1.2 Gy bid 
to 74.4 Gy) [13]. Those authors found a 
mean of 28.6% (range 10.2–58.1%) of the 
mandibular volume was exposed to doses 
higher than the PTD, mainly in the molar 
and retromolar region of the horizontal 
branch. The authors measured a mean 
mandibular volume of 82.3 cm3 (range 
60.1–110.1 cm3); mean cumulative DVH-
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Figure 2. Distribution of various risk factors (RF) for ON in 63 IMRT patients. Risk groups (RG) 
0–VI were defined as follows: patients with doses < 60 Gy to the mandible were classified as 
RG 0; patients with mandible bone doses > 60 Gy as the only risk factor were defined as RG I; 
patients with mandible doses of > 60 Gy plus one of the following RFs were classified as RG II, 
and with all five following as RG VI, respectively: 
• bone infiltration (n = 1), 
• macroscopic tumor-to-bone distance of < 4 mm (n = 33), 
•  ≥ 95% of the SIB delivered to the entire bone diameter to a length of 5–30 mm (n = 16), 
• teeth in the high-dose area (n = 8), 
• ≥ 2 cm3 of the bone exposed to ≥ 70 Gy (n = 5). 
Abbildung 2. ON-Risikofaktoren (RF) bei 63 Patienten. Es wurden Risikogruppen (RG) 0–VI zur 
Abschätzung des ON-Risikos bei IMRT-Patienten gebildet. Patienten mit Kieferdosen < 60 Gy 
wurden der RG 0 zugeordnet, bei Kieferbelastung > 60 Gy der RG I; pro zusätzlichen Risikofak-
tor Zuordnung zur nächsthöheren RG bis hin zu RG VI bei Vorliegen aller folgenden fünf Risi-
kofaktoren zusätzlich zu einer Exposition von > 60 Gy: 
• Knocheninfiltration (n = 1). 
• makroskopische Tumordistanz zum Knochen von < 4 mm (n = 33), 
•  ≥ 95% des Boostvolumens auf einer Länge von 5–30 mm auf den gesamten Knochendurch-
messer appliziert (n = 16), 
• Zähne in der Knochenregion mit hoher Dosis (n = 8), 
•  ≥ 2 cm3 des Knochenvolumens einer Dosis ≥ 70 Gy ausgesetzt (n = 5). 
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based volumes exposed to at least 10%, 
20%, 50%, 80%, and 100% of the PTD 
were approximately 90%, 85%, 75%, 
50%, and 20% of the mandible (Figure 3 
in [13], page 53). In nine patients (50%), 
50% of the mandible received > 88% of 
the PTD. The analysis by Jereczek-Fossa 
et al. represents a careful dosimetric 
evaluation of conformal 3D-CRT as it 
was also a standard schedule in our insti-
tution before IMRT implementation, 
and therefore these data were useful for 
comparative purposes with the dosimet-
ric IMRT data presented in the current 
study. This comparison reveals an ap-
proximate reduction of mandibular vol-
ume exposed to high-dose IMRT of 
~ 15%, 35%, and 17% at doses of > 50%, 
80%, and 100% of PTD, respectively 
(Figure 3). 
Intraindividual dose-volume com-
parisons between 3D-CRT and IMRT 
plans in two patients (one with oropha-
ryngeal and one with nasopharyngeal 
cancer) are reported by Parliament et al. 
[18]. However, mandible bone contour-
ing and dose-volume constraining were 
not specifically performed to spare mandible bone in the 
IMRT cases and therefore these results are of limited com-
parative value. 
In our patients very small partial volumes of the mandibu-
lar bone were exposed to high doses. This was achieved by 
contouring and defining dose-volume constraints for the man-
dibular bone outside the PTV. Dose maxima were “point 
doses” to at least one image voxel; such “hot spots” may blur 
with minimal daily position deviations and therefore they do 
not necessarily reflect true local overdosage. We found that 
the highest dose delivered to the bone was at the lingual cortex 
close to the PTV1, with steep dose gradients toward the buccal 
mandibular cortex in most cases. In 16/63 mandibles, high 
dose encompassed the entire bone diameter across the hori-
zontal branch. The observation of high doses mainly deliv-
ered to the lingual cortex with IMRT may, theoretically, ad-
ditionally reduce the risk of ON, when considering the report 
by Bras et al., hypothesizing the buccal cortex to be at the 
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Figure 3. Dose-volume histograms (DVHs) in 63 patients with complete dosimetric and volu-
metric data. Mean cumulative IMRT DVH (with standard deviations) compared to the mean 
cumulative 3D-CRT DVH (bold values, dotted line) from 18 patients analyzed by Jereczek-Fossa 
et al. [13]: an approximate reduction of 15%, 35%, and 17% of mandibular volumes exposed to 
> 50%, > 80%, and > 100% of prescribed doses was achieved with IMRT technique. 
Abbildung 3. Mittelwerte der Dosis-Volumen-Histogramme (DVHs) von 63 Patienten, deren 
dosimetrische und volumetrische Daten vollständig vorlagen. Mittleres kumulatives IMRT-DVH 
(mit Standardabweichungen) im Vergleich zum mittleren kumulativen DVH von 18 konventio-
nell bifraktioniert bestrahlten Patienten (fette Zahlen, gestrichelte Linie) in der Analyse von 
Jereczek-Fossa et al. [13]: Für die IMRT-bestrahlten Kiefer zeigt sich eine mittlere Reduktion von 
15%, 35% und 17% des Knochenvolumens, das Dosen von > 50%, > 80% und > 100% der Herddo-
sis ausgesetzt war. 
Table 2. Published success rates of endosteal implants in irradiated and nonirradiated jaws from the last few years. An approximately 10% higher 
implant survival rate is reported for nonirradiated mandibles compared to jaws irradiated with doses exceeding ~ 50 Gy. FU time: follow-up time; 
RT: radiotherapy. 
Tabelle 2. Publizierte Erfolgsraten der letzten Jahre für Zahnimplantate in bestrahlten und nichtbestrahlten Kiefern. Es wird ein Implantatüber-
lebensvorteil von ca. 10% für nichtbestrahlte Unterkiefer gegenüber Kieferknochen nach ~ 50 Gy überschreitenden Strahlendosen festgestellt. 
FU time: Beobachtungszeit; RT: Radiotherapie. 
Authors (year) RT Patients (n) Mandible  Implant success  FU time  Recruitment 
   implants (n) rate (%) (years)  interval
Granstrom et al. (2005) [8] Yes 107    471 75   6.3 1979–2003
Visch et al. (2002) [21] Yes 130    446 85 10 1987–2001
Grotz et al. (1999) [11] Yes   47    111 72   5 1988–1997
Esser & Wagner (1997) [6] Yes   60    221 80   5 1985–1995
Weischer & Mohr (1999) [22] Yes   18      83 75/86   7 1988–1991/1992–1997
Weischer & Mohr (1999) [22] No   22      92 86/94   7 1988–1991/1992–1997
Haas et al. (1996) [12] No 714 1 920 90   8.3 1984–1993
Noack et al. (1999) [17] No 883 1 964 94   5 1981–1997
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highest risk [2]. Also in patients with a PTV abutting the man-
dible, the high dose often did not extend over the whole cross 
section. 
This dose reduction translated into a very low ON inci-
dence of one case in 73 patients. In a recently published anal-
ysis of 50 patients treated with IMRT for oropharyngeal can-
cer between 1998 and 2004, one patient was suspected to 
have an ON in an area measuring 5 mm of exposed bone, 
where 70 Gy were delivered. However, radiologic investiga-
tions and further physical examination did not confirm this 
finding, and that patient underwent successful conservative 
treatment [4]. 
Selection of patients “at risk” for ON was performed ac-
cording to the historical 3D-CRT criteria, however, with 
IMRT several of them (15% of the cohort) are no longer “at 
risk”, due to doses < 60 Gy delivered to bone. In consequence, 
an IMRT-adapted ON risk factor score is proposed aiming 
at a more accurate ON risk estimation in IMRT patients (Fig-
ure 2). The observation time is too short to assess the value of 
this scoring system. As only one event happened in our cohort, 
further prospective evaluation is ongoing to assess the signifi-
cance of this intuitively defined risk group system. 
Mandible and soft-tissue conditions are very important in 
postirradiation dental implant and reconstructive procedures. 
Table 2 gives an overview of reported endosteal implant suc-
cess rates in the last few years [6, 8, 11, 12, 17, 21, 22]. These 
data indicate the relevance of bone and adjacent soft-tissue 
irradiation to dental and reconstructive management. 
Based on the presented clinical and dosimetric results, 
the ON incidence rate is expected to decrease from approxi-
mately five events in 100 treated patients (5%) to one to two 
(1–2%). Apart from a substantial gain in terms of quality of 
life [14, 23], generally reduced early and late side effects, and 
a likely improved tumor control, there is also an advantage in 
terms of cost benefit. When the cost for a single incident of 
grade 3 ON is estimated to be 30,000–40,000 Euros, a substan-
tial amount of the additional costs for IMRT treatment would 
be covered.
The documented mandibular protection with IMRT may 
therefore translate into (1) a further reduction of the incidence 
of ON, and (2) a better outcome of osseointegration of im-
plants and posttreatment reconstructive procedures. 
Conclusion 
IMRT permits high-dose irradiation of oropharyngeal and 
oral cavity tumors with good locoregional control, yet with 
very small partial volumes of the mandibular bone exposed to 
high doses. This is expected to translate into a further reduc-
tion of the risk of ON and an improved outcome of osseoim-
plantation in irradiated patients. Longer follow-up and larger 
sample sizes are needed to confirm the reduction in the risk of 
mandibular ON following IMRT. 
Early outcome analysis of endosteal implant survival in 
our IMRT cohort is in preparation. 
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